**Stem cells for muscular dystrophy**

Injection of a class of stem cells found in blood vessels, known as mesoangioblasts, can restore muscle in a mouse model of muscular dystrophy, report researchers in *Science* (July 10). The scientists found that intra-arterial injection of wild-type mesoangioblasts into mice lacking the a-sarcoglycan gene-a model of limb-girdle muscular dystrophy---corrects the dystrophic phenotype of almost all muscles downstream of the injection site. The researchers suggest the success of this method is mainly due to the widespread distribution of donor stem cells through the capillary network and into muscle tissue, where they are incorporated into regenerating fibres.

**Trial of kala azar drug launched**

WHO and the Institute for OneWorld Health, a non-profit US pharmaceutical company, have launched a phase III trial of the off-patent drug paromomycin for treatment of kala azar, or visceral leishmaniasis. The multicentre trial of 670 patients is funded by the Bill and Melinda Gates Foundation and will take place in India, which has the largest burden of visceral leishmaniasis in the world. For a lifelong cure, the drug is expected to cost US\$21 in total, or \$1 per day for the 3-week treatment.

**Brain differences in PTSD**

Individuals with post-traumatic stress disorder (PTSD) have a significant reduction in grey matter volume in a region of the brain involved in attention and emotional regulation, researchers in Japan report this week. The investigators studied nine victims of the Tokyo subway sarin attack who had PTSD and 16 matched victims of the attack who did not have PTSD. They found a reduction in grey matter in the left anterior cingulate cortex in those with PTSD compared with individuals without the disorder (*Proc Natl Acad Sci USA*, published online July 7; [DOI 10.1073/pnas.1530467100](10.1073/pnas.1530467100)). The researchers say these findings provide support for the important role of the anterior cingulate cortex in the pathology of PTSD.

**Bush lands in Africa**

US President George Bush arrived in Senegal on July 8 with promises of aid and a message of hope. He will be visiting five nations in Africa and, by focusing on different problems in each country, he will try to promote his \$15 billion 5-year anti-AIDS initiative, economic development, and trade liberalisation. Bush hopes to enter his 2004 re-election campaign attracting more African-American support, after dismissing Africa as outside US security interests during his 2000 campaign.

**SARS-masks off**

Taiwan, the last region affected by severe acute respiratory syndrome (SARS), was removed from WHO\'s list of infected areas. The illness seems to have been contained; however, there are still fears that the virus could return because, as WHO Director-General Go Harlem Brundtland warned, a single case can spark a new outbreak, and it is possible that SARS cases may have slipped through the surveillance net.

**New malaria vaccine tested**

A new malaria vaccine candidate is to be tested in a phase II paediatric clinical trial. The international partnership will test the safety and efficacy of GlaxoSmithKline Biological\'s vaccine (RTS,S/AS02A) in children in Mozambique. Malaria is the most important health problem in many parts of sub-Saharan Africa and Asia, and although results are not expected for about 2 years, researchers are confident the trial will at least bring them closer to the goal of immunising children against malaria.

**West Nile disease and paralysis**

Paralysis is a significant cause of complications in patients affected by West Nile virus, say researchers in *Neurology* (July 8). As well as already known symptoms such as rash, altered mental status, low back pain, and gastrointestinal complaints, muscle weakness is another important aspect of the disease, and occurred in half of the 23 patients examined. According to the research, paralysis can involve all four limbs and respiratory muscles, and many patients require mechanical ventilation.

**Surgery on Iranian twins fails**

Ladan and Laleh Bijani, the conjoined Iranian twins, died on July 8 in Singapore. After an unpredicted 53-h operation to separate their enmeshed brains and massive blood loss, the team of 28 doctors was unable to stabilise their blood circulation. According to the doctors, as well as sharing an important vein, the twins\' brains were fused together and a large amount of blood vessels and tissue had to be separated, making the operation more complex than anticipated.

**Boost for stem-cell research**

To head off a ban on the controversial technology, the European Commission will adopt new guidelines regulating the use of embryos in EU-funded research. The change will take place this week as part of an attempt to have comprehensive guidelines in place before the research moratorium finishes at the end of 2003. Scientists in favour of more stem-cell research believe it could result in cures for many diseases such as diabetes and Alzheimer\'s. But some opponents argue that more studies could end in designer babies and reproductive cloning.

**HIV increases in eastern Europe**

HIV infection is spreading rapidly among young eastern Europeans, said health authorities in Germany this week. At the German AIDS Foundation, Professor Reinhard Kurth, president of the Robert Koch Institute, said the proportion of young people infected with HIV is twice as high in eastern Europe as it is in the west. More than 75% of those infected in eastern Europe are younger than 30 years old, he said. Central Asian and Caucasus regions are newly affected areas, said Kurth. Of particular concern is the rise in HIV-infected women, which has increased from 12% to 25% over the past 10 years.
